Abstract

Serum carcinoembryonic antigen (CEA) is the most commonly used tumor marker in a variety of cancers including colorectal cancer (CRC) for tumor diagnosis and monitoring. Recent studies have shown that colonic crypt cells expressing little or no CEA may enrich for stem cells. Numerous studies have clearly shown that there exist CRC patients with normal serum CEA levels during tumor progression or even tumor relapse, although CEA itself is considered to promote metastasis and block cell differentiation. These seemingly contradictory observations prompted us to investigate, herein, the biological properties as well as tumorigenic and metastatic capacity of CRC cells that express high (CEA+) versus low CEA (CEA−/lo) levels of CEA. Our findings show that the abundance of CEA−/lo cells correlate with poor differentiation and poor prognosis, and moreover, CEA−/lo cells form more spheres in vitro, generate more tumors and exhibit a higher potential in developing liver and lung metastases than corresponding CEA+ cells. Applying RNAi-mediated approach, we found that IGF1R mediated tumorigenic and capacity of CEA−/lo cells but did not mediate those of CEA+ cells. Notably, our data demonstrated that CEA molecule was capable of protecting CEA−/lo cells from anoikis, implying that CEA+ cells, although themselves possessing less tumorigenic and metastatic capacity, may promote metastasis of CEA−/lo cells via secreting CEA molecule. Our observations suggest that, besides targeting CEA molecule, CEA−/lo cells may represent a critical source of tumor progression and metastasis, and should therefore be the target of future therapies.

Highlights

  • Colorectal cancer (CRC) is the third most common cause of death from cancer [1]

  • We first studied the correlations of preoperative serum carcinoembryonic antigen (CEA), quantified proportions of CEA+/CEA-/lo colorectal cancer (CRC) cells and tumor grade

  • CEA was first identified as a tumor associated antigen from human colon cancer tissue extracts in 1965 by Gold and Freedman [28]

Read more

Summary

Introduction

Colorectal cancer (CRC) is the third most common cause of death from cancer [1]. CRC is heterogeneous, manifesting variegated cellular morphologies and histopathological presentations. Serum carcinoembryonic antigen (CEA) is recommended as a tumor marker in colorectal cancer (CRC) for tumor detecting and monitoring response to therapy [2]. It is characterized as a member of CD66 cluster of differentiation and several studies have provided evidence that CEA protein blocks cell differentiation and promote tumor progression [3, 4]. Welldifferentiated CRCs produce more CEA in serum and primary tissues than poorly differentiated specimens [7, 8] It is not defined whether free CEA protein or cellular CEA or both take effects in cell differentiation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call